Ivaylo Dimitrov

Dr. Ivaylo Dimitrov

Auckland Cancer Society Research Centre

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2019 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
IDIvaylo Dimitrov
Ivaylo Dimitrov
MHMartyn Harvey
Martyn Harvey
LVLogan J. Voss
Logan J. Voss
JSJames W. Sleigh
James W. Sleigh
MBMichael J. Bickerdike
Michael J. Bickerdike
WDWilliam A. Denny
William A. Denny

5 October 2020 in Synthesis
Verified
Journal Article
Closed access
PDF file
IDIvaylo Dimitrov
Ivaylo Dimitrov
ESElina E. K. Suonio
Elina E. K. Suonio
Propofol (2,6-diisopropylphenol) is an intravenous sedative/hypnotic agent that is used extensively for introduction and maintenance of general anaesthesia, sedation of critically ill patients and procedural sedation (e.g., endoscopy). Propofol has a rapid onset and offset of action and shows only minimal accumulation upon prolonged use. Propofol is only sparingly soluble in water and is currently marketed in 10% soybean oil-based lipid emulsion. Propofol’s anaesthetic properties were discovered over forty years ago, and it has been in clinical use for over thirty years. The main use of propofol remains as an anaesthetic but, over the years, analogues have been developed with varying properties from anticancer, anticonvulsant and antioxidant. In addition, large synthetic efforts have been made towards improving propofol’s water-solubility, its activity, and elucidating its structure–activity­ relationship and exact mechanism of action have been made. This review provides an overview of the research pertaining to propofol-like molecules and covers the efforts of synthetic chemists towards propofol analogues over the last 40 years. 1 Introduction 2 History 3 Early Work 4 Improving Water Solubility 5 The Importance of the Phenol 6 Exploring the Structure–Activity Relationship and Attempts to Improve Activity 7 Anticancer Activity 8 Anticonvulsant Properties 9 Antioxidant Activity 10 Photoactive Labelling to Elucidate Mechanism of Action 11 Photoregulation 12 Conclusion Received: 31 May 2020 Accepted after revision: 22 August 2020 Publication Date: 05 October 2020 (online) © 2020. Thieme. All rights reserved Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

26 June 2020 in Molecules
Verified
Journal Article
Open access
PDF file
IDIvaylo Dimitrov
Ivaylo Dimitrov
MHMartyn Harvey
Martyn Harvey
LVLogan Voss
Logan Voss
JSJames W. Sleigh
James W. Sleigh
MBMichael J. Bickerdike
Michael J. Bickerdike
BDBill Denny
Bill Denny
A series of benzene ring substituted ketamine N-alkyl esters were prepared from the corresponding substituted norketamines. Few of the latter have been reported since they have not been generally accessible via known routes. We report a new general route to many of these norketamines via the Neber (oxime to α-aminoketone) rearrangement of readily available substituted 2-phenycyclohexanones. We explored the use of the substituents Cl, Me, OMe, CF3, and OCF3, with a wide range of lipophilic and electronic properties, at all available benzene ring positions. The 2- and 3-substituted compounds were generally more active than 4-substituted compounds. The most generally acceptable substituent was Cl, while the powerful electron-withdrawing substituents CF3 and OCF3 provided fewer effective analogues.

19 December 2019 in BMC Pharmacology and Toxicology
Verified
Journal Article
Open access
PDF file
MHMartyn Harvey
Martyn Harvey
JSJamie Sleigh
Jamie Sleigh
LVLogan Voss
Logan Voss
MBMike Bickerdike
Mike Bickerdike
IDIvaylo Dimitrov
Ivaylo Dimitrov
BDBill Denny
Bill Denny
Background: Ketamine, a widely used anaesthetic and analgesic agent, is known to improve the analgesic efficacy of opioids and to attenuate central sensitisation and opioid-induced hyperalgesia. Clinical use is, however, curtailed by unwanted psychomimetic effects thought to be mediated by N-methyl-D-aspartate (NMDA) receptor antagonism. KEA-1010, a ketamine ester-analogue designed for rapid offset of hypnosis through hydrolysis mediated break-down, has been shown to result in short duration sedation yet prolonged attenuation of nociceptive responses in animal models. Here we report on behavioural effects following KEA-1010 administration to rodents. Methods: KEA-1010 was compared with racemic ketamine in its ability to produce loss of righting reflex following intravenous injection in rats. Analgesic activity was assessed in thermal tail flick latency (TFL) and paw incision models when injected acutely and when co-administered with fentanyl. Tail flick analgesic assessment was further undertaken in morphine tolerant rats. Behavioural aberration was assessed following intravenous injection in rats undergoing TFL assessment and in auditory pre-pulse inhibition models. Results: KEA-1010 demonstrated an ED50 similar to ketamine for loss of righting reflex following bolus intravenous injection (KEA-1010 11.4 mg/kg [95% CI 10.6 to 12.3]; ketamine (racemic) 9.6 mg/kg [95% CI 8.5–10.9]). Duration of hypnosis was four-fold shorter in KEA-1010 treated animals. KEA-1010 prolonged thermal tail flick responses comparably with ketamine when administered de novo, and augmented morphine-induced prolongation of tail flick when administered acutely. The analgesic effect of KEA-1010 on thermal tail flick was preserved in opioid tolerant rats. KEA-1010 resulted in increased paw-withdrawal thresholds in a rat paw incision model, similar in magnitude yet more persistent than that seen with fentanyl injection, and additive when co-administered with fentanyl. In contrast to ketamine, behavioural aberration following KEA-1010 injection was largely absent and no pre-pulse inhibition to acoustic startle was observed following KEA-1010 administration in rats. Conclusions: KEA-1010 provides antinociceptive efficacy in acute thermal and mechanical pain models that augments standard opioid analgesia and is preserved in opioid tolerant rodents. The NMDA channel affinity and psychomimetic signature of the parent compound ketamine is largely absent for KEA-1010.

11 April 2019 in BMC Genomics
Verified
Journal Article
Open access
PDF file
GJGregory Jacobson
Gregory Jacobson
LVLogan Voss
Logan Voss
Anica KlockarsAnica Klockars
Anica Klockars
SBSteve Bird
Steve Bird
IDIvaylo Dimitrov
Ivaylo Dimitrov
MHMartyn Harvey
Martyn Harvey
Ketamine ester analogs, SN 35210 and SN 35563, demonstrate different pharmacological profiles to ketamine in animal models. Both confer hypnosis with predictably rapid offset yet, paradoxically, SN35563 induces a prolonged anti-nociceptive state. To explore underlying mechanisms, broad transcriptome changes were measured and compared across four relevant target regions of the rat brain. SN 35563 produced large-scale alteration of gene expression in the Basolateral Amygdala (BLA) and Paraventricular Nucleus of the Thalamus (PVT), in excess of 10x that induced by ketamine and SN 35210. A smaller and quantitatively similar number of gene changes were observed in the Insula (INS) and Nucleus Accumbens (ACB) for all three agents. In the BLA and PVT, SN 35563 caused enrichment for gene pathways related to the function and structure of glutamatergic synapses in respect to: release of neurotransmitter, configuration of postsynaptic AMPA receptors, and the underlying cytoskeletal scaffolding and alignment. The analgesic ketamine ester analog SN 35563 induces profound large-scale changes in gene expression in key pain-related brain regions reflecting its unique prolonged pharmacodynamic profile.